Medication-related osteonecrosis of the jaw: prevention and medical-surgical management through low-level laser therapy with different wavelengths

Medication-related osteonecrosis of the jaw (MRONJ) is on the rise among patients taking long-term antiresorptive drugs. The primary goal of treatment in osteonecrosis of the jaws (ONJ) should be to improve the patient's quality of life by managing pain and infections, preventing the development of new lesions and slowing the progression of the disease. In recent years, the use of the laser for MRONJ treatment has spread, thanks to the practical administration and the widely reported beneficial effects on tissue healing. This literature overview sought to clarify whether low-level laser therapy (LLLT) has positive effects on the treatment of osteonecrosis of the jaw. Our results show that treatment modalities, including LLLT, were associated with superior outcomes in terms of cure or improvement of antiresorptive drugs-related osteonecrosis of jaw lesions compared to conventional surgical and / or conservative drug therapy alone. It can be concluded that combined treatment with antibiotics, minimally invasive surgery (including laser surgery) and LLLT in the early stages of the disease should be the gold standard for management to MRONJ.